To Evaluate the Safety and Tolerability of SYHX2001 in Patients With Advanced or Metastatic Solid Tumors

Phase 1 Unknown 176 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, multicenter, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the experimental drug(SYHX2001) in previously treated patients with advanced or metastatic cancer.

Timeline

Start: 2022-07-27
Primary completion: 2026-01-06
Completion: 2026-01-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SYHX2001	Unknown	—	Oral

Indications

No indication recorded.